Sunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference
06 February 2017 - 11:00PM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that
Daniel Swisher, Chief Executive Officer of Sunesis, will present at
the 19th Annual BIO CEO & Investor Conference on Monday,
February 13th at 5:30 PM Eastern Time at the Waldorf Astoria Hotel
in New York.
A live webcast of the presentation will be
available on the Sunesis website at http://ir.sunesis.com. A replay
of the webcast will be archived on the "Calendar of Events" page in
the Investors and Media section of the Sunesis website for two
weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company focused
on the development and commercialization of new oncology
therapeutics for the potential treatment of solid and hematologic
cancers. Sunesis has built a highly experienced cancer drug
development organization committed to improving the lives of people
with cancer. Currently, the company is focused on pursuing
regulatory approval in Europe for its lead product
candidate, vosaroxin, for the treatment of relapsed or refractory
acute myeloid leukemia in patients aged 60 and older, as well as
advancing its novel kinase-inhibitor pipeline, which includes its
proprietary non-covalent BTK-inhibitor, SNS-062.
For additional information on Sunesis, please
visit http://www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles